secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001628280-23-041308
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat
--------------------------------------------------------------------------------

- Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.
- Gross margin fell to 42.8% from 47.9% on lower revenue and fixed costs.
- FY2024 revenue guidance revised to be generally flat YoY, citing customer cancellations.
- Hired Brady Davis as President to lead new strategic initiatives.
- Corellia AI drug discovery advancing with two lead targets; seeking capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/csbr-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-041308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer